Product: Recombinant Mouse IL-13 (carrier-free)

Catalog No.: 575908

Michael Tuvim, Professor UT MD Anderson Cancer Center

Consistent IL-13
Overall:	Product Quality:	Ease of Use:
Reasonably priced and high quality.

Experimental Design

Application:	In vivo application; Induction of secreted mucins from perfused tracheas
Cells used:	Sedated mouse
Brief Protocol:	Mucous metaplasia of tracheal epithelial cells was induced by the instillation of IL-13 (40 ng/μl IL-13, 2 μl/g body weight; BioLegend) into the oropharynx of mice under isoflurane anaesthesia.The mice were administered IL-13 on two successive days and on the third day were killed and the tracheas harvested by dissection. The tracheas were cannulated at their proximal ends, mounted vertically in a perfusion chamber and perfused with DMEM culture medium at 10 μl/min for a 2 h equilibration period. After equilibration, 50 μl fractions were collected every 5 min for a 30 min baseline period, then the perfusate was switched to one containing ATPγ S (100 μM) and fractions were collected for another 30 min. The fractions were assessed for released mucins by ELISA.
Results Summary:	IL-13 administration as described results in robust and consistent mucous metaplasia.
Additional Notes:	Image below shows mucous metaplasia of mouse airway epithelium. Mucin is shown in red.

Data Image Click on the image for full size data.

Publication Status This data has been published. Pubmed

See all Reviews